Benchmark's UK antigen facility starts production
Benchmark Holdings
39.00p
16:30 27/11/24
Benchmark's £17m vaccine antigen production facility in Braintree, Essex, has processed its first commercial-scale batch of antigen for use in aquaculture vaccines.
FTSE AIM 100
3,566.10
16:49 27/11/24
FTSE AIM All-Share
731.40
16:59 27/11/24
Pharmaceuticals & Biotechnology
20,186.36
16:59 27/11/24
Antigens, which are capable of stimulating immune response in animals and humans, will be produced from the facility for a number of new aquaculture vaccines in Benchmark's product pipeline, the company said on Tuesday.
The facility where the substance is being produced commenced operations on 29 September 2017, with work on the final validation of the facility also underway, to ensure compliance with EU Good Manufacturing Practices.
Once fully licensed, the increased capacity of the 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe, enabling the company to significantly expand the number and range of vaccines it produces.
Benchmark shares were up almost 5% to 44p in early trading on Tuesday.